| Nov 11 |
Neurogene plummets 35% on gene therapy trial data for Rett syndrome
|
| Nov 6 |
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
|
| Oct 22 |
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
|
| Oct 16 |
Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds?
|
| Oct 14 |
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
|
| Oct 14 |
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
|
| Oct 3 |
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
|
| Sep 26 |
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
|
| Sep 19 |
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
|
| Aug 18 |
Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
